Increasing evidence suggests that aberrant activation of Wnt signaling is involved in tumor development and progression. Our earlier study on gene expression profile in human gliomas by microarray found that some members of Wnt family were overexpressed. To further investigate the involvement of Wnt signaling in gliomas, the expression of core components of Wnt signaling cascade in 45 astrocytic glioma specimens with different tumor grades was examined by reverse transcription-PCR and immunohistochemistry. Wnt2, Wnt5a, frizzled2 and b-catenin were overexpressed in gliomas. Knockdown of Wnt2 and its key mediator b-catenin in the canonical Wnt pathway by siRNA in human U251 glioma cells inhibited cell proliferation and invasive ability, and induced apoptotic cell death. Furthermore, treating the nude mice carrying established subcutaneous U251 gliomas with siRNA targeting Wnt2 and b-catenin intratumorally also delayed the tumor growth. In both in vitro and in vivo studies, downregulation of Wnt2 and b-catenin was associated with the decrease of PI3K/p-AKT expression, indicating the interplay between Wnt/b-catenin and PI3K/AKT signaling cascades. In conclusion, the canonical Wnt pathway is of critical importance in the gliomagenesis and intervention of this pathway may provide a new therapeutic approach for malignant gliomas.
Introduction
Wnts belong to a large family of cysteine-rich secreted glycoproteins, consisting of at least 19 members in humans. [1] [2] [3] Wnts play important roles in multiple cellular processes during development, including cell differentiation, migration, polarity and proliferation. 1, 3 Wnt signals are transduced through at least three distinct signaling pathways, including canonical Wnt/b-catenin, Wnt/polarity and Wnt/calcium pathways. The major function of the canonical Wnt/b-catenin signaling pathway is to regulate cell differentiation and proliferation during development through the b-catenin/T-cell factormediated activation of Wnt target genes. The Wnt/ polarity pathway regulates cell polarity and morphogenetic movements through the activation of c-Jun Nterminal kinase. The Wnt/calcium pathway regulates cell adhesion and motility through the activation of phospholipase C, protein kinase C and Ca 2 þ -calmodulindependent kinase II. 1, 4, 5 Among these three signaling pathways, the canonical Wnt/b-catenin pathway is most extensively studied and has been implicated in tumorigenesis.
Receptors for Wnt ligands contain at least 11 identified frizzled (Fz) transmembrane proteins. Most Wnt proteins bind to multiple Fz and vice versa. 2, 5, 6 However, recent studies show that one Wnt protein is able to signal in two distinct pathways depending on the receptor context. 3, 5, 7 The complexity of specific ligand-receptor pairings remains unclear. [1] [2] [3] 5, 7, 8 It is proposed that Wnt signaling is initiated after Wnt ligand binding to its target Fz and co-receptor, low-density lipoprotein receptor-related proteins LRP5 or LPR6. 3, 4, 8, 9 In the absence of the Wnt signals, an intracellular multiprotein complex consisting of adenomatous polyposis coli (APC), axin, glycogen synthase kinase-3b (GSK-3b) and b-catenin can phosphorylate b-catenin, leading to its subsequent ubiquitination and degradation. On activation of Wnt, the Wnt ligand binds to its Fz receptor and transduces the signal to a cytoplasmic protein Dishevelled (Ds), which in turn inhibits the serine/threonine kinase GSK-3b. The decreased activity of GSK-3b leads to inactivation and dissociation of the multiprotein degradation complex, resulting in the accumulation and nuclear translocation of cytosolic b-catenin. The b-catenin is the key mediator of canonical Wnt signaling and nuclear b-catenin is the hallmark of an active Wnt pathway. 1, 2, 8 In the nucleus, b-catenin interacts with T-cell factor/LEF transcription factors and activates downstream target genes, including c-Myc, cyclin D1, c-Jun, c-fos, fra-1,and members of AP-1 family, that are mainly involved in the regulation of cell fate and proliferation. 2, 8, 10 In addition to their roles during the development and adult tissues, the alteration of components of the Wnt pathway has also been implicated in oncogenesis. Most notably, up to 85% of all sporadic colorectal cancers (CRCs) have mutations in APC, and b-catenin mutations are present in approximately 10% of the remaining CRCs. 8 There are many ways to activate Wnt signaling; although APC mutation is frequently found in the majority of CRCs, it rarely occurs in cancers originating outside of the gastrointestinal tract. 11 The mutations of bcatenin have been identified in a variety of tumors. However, the alteration of Wnt per se is less studied in tumorigenesis. In our earlier study, the gene expression profiles of 63 samples of different pathological types of human gliomas and 5 samples of human normal brain tissues were analyzed using Atlas Human Cancer Array 1.2, and overexpression of some members of the Wnt pathway were observed in gliomas. 12, 13 To further evaluate the exact role of Wnt in gliomagenesis, we analyzed the expression of Wnts in more fresh samples of primary astrocytic gliomas in the current study. We confirmed that Wnt2 and Wnt5a were significantly overexpressed in gliomas. As it is generally accepted that Wnt5a activates the non-canonical Wnt pathway, which is b-catenin independent, 14 only the effects of downregulation of Wnt2 and b-catenin in the canonical Wnt pathway by siRNA were investigated in cultured malignant glioma cells and established subcutaneous gliomas in nude mice.
Materials and methods

Tissue samples
In total, 45 freshly resected astrocytic glioma samples were collected at the Department of Neurosurgery at Tianjin Medical University General Hospital during 2004 and classified according to WHO (World Health Organization) categories (2000) . Tissues and clinical information are obtained as part of an approved study at the University. There are 19 cases of WHO II grade tumors, including 17 cases of protoplasmic and fibrillary astrocytomas and 2 cases of oligodendroastrocytomas, 13 cases of anaplastic astrocytomas (WHO III grade) and 13 cases of glioblastomas (WHO IV grade). Four normal brain tissue specimens were obtained from internal decompression of patients with cerebral injury and temporal lobe resection for epilepsy. A portion of each tissue sample was snap frozen in the liquid nitrogen following resection and stored at À70 1C for isolation of RNA, and the remaining portion was fixed with 10% formalin for histopathological and immunohistochemical examination. All the tumor or normal brain tissues were diagnosed by two independent neuropathologists. The expression of core components of the Wnr/b-catenin signaling pathway in these samples was examined by reverse transcription (RT)-PCR analysis and immunohistochemical staining. The correlation of expression with the degree of malignancy of gliomas was determined.
RT-PCR analysis
For RT-PCR analysis, total RNA was extracted from tissue samples using Trizol reagent (Invitrogen, Carlsbad, CA), reverse-transcribed to cDNA and amplified by PCR. The following PCR conditions for amplification of Wnts and its receptor Fz2, Fz5 and b-catenin were used: initial denaturation at 94 1C for 2 min, then 94 1C for 30 s, 52 1C for 30 s and 72 1C for 30 s for 30 cycles; after the final cycle, the reaction was held at 72 1C for 5 min. A portion of b-actin gene was also amplified under the same conditions as a control. PCR products were electrophoresed on 2% agarose gel. The gel was stained with ethidium bromide, digitally photographed and scanned with UVI Gel Analyzing System (UVI Tech, Cambridge, England). Gene expression was calculated as the ratio of mean band density of RT-PCR products to that of the internal b-actin control. The pairs of primers used to amplify each type of cDNA were as follows:
Immunohistochemical staining For immunohistochemical staining, formalin-fixed tissue samples were prepared as paraffin-embedded sections and stained with hematoxylin and eosin for histopathological diagnosis. Unstained sections were deparaffinized and incubated overnight at 4 1C with primary antibodies against the proteins described above (Santa Cruz, San Diego, CA; in 1:100 dilution), then with biotinylated secondary antibody in a dilution of 1:200 at room temperature for 1 h, followed by incubation with ABC peroxidase and diaminobenzedine. The sections were counterstained with hematoxylin. The expression levels of Wnt2, Fz2 and b-catenin in each specimen were scored Cell culture and transfection Human glioblastoma U251MG cell line was obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Science. Cells were cultured in sixwell plates in DMEM supplemented with 10% fetal calf serum. At 24 h after plating, the complete medium was replaced with serum-free medium. Cells were then transfected with 20 ng/10 ml siRNA using lipofectamine (Invitrogen). After 6 h, serum-free medium was replaced again with complete medium and cultured at 37 1C in 5% CO 2 . The target siRNA sequences against Wnt2 and bcatenin were 5 0 -GAAGATGGGAAGCGCCAAG-3 0 and 5 0 -CAGGGGGUUGUGGUUAAGCUCUU-3 0 , respectively. A scramble siRNA sequence (5 0 -TTCTCCGAAC GTGTCACGT-3 0 ) was used as a control (Gima Biol Engineering Inc., Shanghai, China).
Western blot analysis
At 48-72 h after transfection with Wnt2 or b-catenin siRNA, total proteins from control and transfected U251 glioma cells were extracted and the protein concentration was determined by Lowry method. 40 mg of protein lysates from each sample was subjected to SDS-PAGE on 10% SDS-polyacrylamide gel. Separated proteins were transferred to a PVDF membrane The membrane was incubated with primary antibodies against Wnt2, Fz2, pGSK3b, b-catenin, PI3K, p-AKT, cyclin D1 and c-Myc (Santa Cruz; 1:500 dilution), followed by HRP-conjugated secondary protein (Zymed, San Diego, CA; 1:1000 dilution). The specific protein was detected using a SuperSignal protein detection kit (Pierce, USA). After washing, the membrane was reprobed with an antibody against b-actin (1:500 dilution). The band density of specific proteins was quantified after normalization with the density of b-actin.
Immunofluorescence staining
At 48-72 h after transfection with siRNA, the transfected and parental cells growing on the coverslips were fixed with À20 1C methanol, blocked with 1% BSA-PBS for 30 min and incubated overnight at 4 1C with primary antibodies (1:100 dilution) against Wnt2, Fz2, p-GSK3b, b-catenin, PI3K, p-AKT, cyclin D1 and c-Myc, then incubated with fluorescein isothiocyanate/tetraethyl rhodamine isothiocyanate (TRITC)-labeled secondary antibody (1:200 dilution) for 30 min at 37 1C, washed with PBS and mounted with 0.5 M Na 2 CO 3 -50% glycerol. The images were captured by a fluorescence microscope.
MTT assay
The viability of control and siRNA-transfected U251 cells was measured by MTT (3-(4,5-dimethylthiazol-2)-2,5-diphenyltetrazolium bromide) assay. Briefly, 4 Â 10 3 cells were plated into each well of a 96-well plate. At 24, 48 and 72 h after plating, 20 ml of MTT (5 mg ml
À1
) was added to each well and incubated for additional 4 h at 37 1C. The reaction was stopped by lysing the cells with 200 ml of DMSO for 5 min. Optical density was measured at 570 nm and data were expressed as the percentage of control.
Flow cytometric analysis of cell cycle kinetics Parental and transfected U251 cells in the log phase of growth were harvested and fixed with 75% ethanol overnight at 4 1C, and then incubated with RNase at 37 1C for 30 min. Cell nuclei were stained with propidium iodide for 30 min. A total of 10 000 nuclei were examined by a FACS Calibur flow cytometer and DNA histograms were analyzed by Modifit software (Becton Dickinson, Franklin Lakes, NJ).
Detection of cell apoptosis by Annexin staining and TUNEL method
Annexin V-cy3-labeled Apoptosis Detection kit 1 (Abcam, Cambridge, England) was used for detection of apoptotic cells by flow cytometry as described earlier. 15 The data were analyzed using Cell Quest software (Becton Dickinson). The extent of cell apoptosis in the tumor specimens was evaluated by TUNEL (TdT-mediated dUTP nick end labeling) method using an in situ Cell Death kit (Roche, Basel, Switzerland). Cell nuclei were counterstained with Hoechst 33342, visualized by fluorescent microscopy and analyzed by IPP5.1 (Olympus, Tokyo, Japan).
Three-dimensional cell growth on matrigel Each well of a 24-well plate was precoated with 200 ml of undiluted phenol red-free matrigel (BD Biosciences, USA). At 6 h after transfection with siRNA, cells were harvested, diluted to a density of 2 Â 10 4 in 200 ml of complete medium per well, mixed with 100 ml of undiluted ice-cold matrigel for a ratio of 2:1 (v/v) and laid over the bottom layer. After gelling, complete culture medium was added and changed every 2-3 days. Cell morphology was assessed at day 14 by capturing images at Â 40 magnification.
Establishment of subcutaneous glioma model and treatment with siRNA targeting Wnt2 and b-catenin All the animal experiments were carried out according to the regulations and internal biosafety and bioethics guidelines of Tianjin Medical University and Tianjin Municipal Science and Technology Commission. Female immune-deficient nude mice (6 weeks old; BALB/C-nu) were purchased from the animal center at the Cancer Institute of the Chinese Academy of Sciences, bred at the facility of laboratory animals, Tianjin Medical University, and housed in microisolator individually ventilated cages with water and food. A subcutaneous U251 glioma xenograft model was established as described earlier. 16 Once the tumor size reached approximately 5 mm in diameter, the mice were randomly divided into four groups (eight mice per group): (1) control untreated group; (2) Wnt2 siRNA-treated group; (3) b-catenin siRNA-treated group and (4) scramble siRNA (scr-siRNA) treated group. siRNA/oligofectamine mixture (25 ml) containing 400 pmol of Wnt2 or b-catenin siRNA was injected intratumorally. The same amount of scramble siRNA was used for control treatment. Because of the short effect of synthetic siRNA, the siRNAs were injected every 4 days until the end of experiment. During the 32-day observation period, the tumor volume was measured with a caliper every 3 days using the following formula: volume ¼ length Â width 2 /2. At the end of observation, the mice were killed and the tumor specimens were prepared as paraffin-embedded sections. The expression levels of Wnt2, Fz2, p-GSK3b, b-catenin, PI3K, p-AKT, cyclin D1 and c-Myc were examined by immunohistochemical staining and cell apoptosis was determined by the TUNEL method.
Statistical analysis
A commercially available software package SPSS10.0 was employed for statistical analysis of the data obtained. One-way analysis of variance and Spearman rank correlation analysis were used to analyze the significance between groups. The LSD method of multiple comparisons with parental and control groups was used when the probability for analysis of variance was statistically significant. Statistical significance was determined at Po0.05 level.
Results
The expression of the major components of Wnt signaling pathway in gliomas The mRNA expression of the important members of Wnt ligands and receptors, as well as its mediator b-catenin, was determined by RT-PCR in 45 astrocytic glioma specimens and 4 normal brain samples. The expression of Wnt2, Wnt5a and Fz2 mRNA was significantly upregulated in gliomas as compared with normal brain samples. There was no mRNA differential expression of Wnt3, Wnt4, Wnt10b, Wnt13, and b-catenin between glioma and normal brain tissues, whereas Wnt1 and Fz5 mRNA showed either trace or no expression in normal brain or glioma samples (Figures 1a and b) .
On the basis of the RT-PCR results, the expression of Wnt2, Fz2, b-catenin and the downstream effectors cyclin D1 and c-Myc, as well as PI3K and p-AKT, were examined by immunohistochemistry. Wnt2, Fz2 and bcatenin were overexpressed in astrocytic gliomas as compared with the normal brain tissues, and their expression levels were elevated with the ascending order of tumor malignancy (Table 1) . It is interesting to note that no mRNA differential expression of b-catenin was observed between normal brain tissues and different grades of gliomas, whereas b-catenin protein expression was markedly higher in gliomas than that in normal brain tissues, and the expression was further enhanced with the increasing malignant degree of tumors. These results indicate that increased b-catenin protein expression may not be the result of the increased transcription, but is likely derived from the inhibition of its degradation. The expression of cyclin D1, c-Myc, PCNA, PI3K and p-AKT was also elevated in gliomas and higher in malignant gliomas than in low-grade gliomas (Figure 1c) . Spearman rank correlation analysis showed that Wnt2 expression was positively correlated with the expression of all these proteins. (Figures 2b and c) .
Western blot analysis and immunostaining of
The effect of Wnt2 and b-catenin siRNA on the viability, apoptosis and invasive ability of U251 cells The viability of U251 cells transfected with siRNAs was determined by MTT assay. The viability of the cells transfected with either Wnt2 or b-catenin siRNA was decreased starting 24 h after transfection and continued to reduce during the 3-day observation period, whereas the viability of the cells transfected with scramble siRNA was not suppressed as compared with the parental cells. There was no significant difference in the decrease in cell viability using either Wnt2 or b-catenin siRNA (Figure 3a) .
The cell cycle kinetics of the parental and transfected cells showed that the S-phase fraction was decreased and the cell cycle was arrested in G0/G1 phase in U251 cells transfected with Wnt2 siRNA and b-catenin siRNA as compared with control cells (Figure 3b ). These results indicate the delay in cell cycle progression and decrease in cell proliferation in U251 cells transfected with siRNA targeting Wnt2 or b-catenin.
Annexin V staining showed that apoptotic cells in U251 cells transfected with Wnt2 or b-catenin siRNA were significantly increased as compared with those in the parental cells and cells transfected with scramble siRNA (Figure 3c ). These findings suggest that siRNA targeting Wnt2 and b-catenin is able to induce apoptosis in glioma cells.
Invasive growth is an important biological characteristic of malignant glioma cells. The invasive ability of U251 cells transfected with siRNA targeting Wnt2 or bcatenin was assessed by in vitro three-dimensional cell growth in matrigel matrix. The parental U251 cells and cells transfected with scramble siRNA grew as aggregated colonies from which highly invasive cells spread to form dendritic extensions, whereas the cells transfected with siRNA targeting Wnt2 or b-catenin formed colonies without or with only traces of extended branching (Figure 3d ). These results suggest that knockdown of Wnt2 and b-catenin expression reduces the aggressive capability of malignant glioma cells. . During the first 2 weeks of the observation period, the tumors in either control or treated groups grew slowly and there was no marked difference in tumor size between them. However, starting at day 16 after the first treatment, the tumors in the control and scr-siRNAtreated mice grew rapidly until the end of the observation (Figures 4a and b) . There was significant difference in tumor volume between the control and Wnt2-or b-catenin siRNA-treated mice in the last half of the observation period (Po0.01), but no difference in tumor volume between Wnt2-and b-catenin siRNA-treated mice.
Expression of Wnt2, b-catenin and related proteins in tumors treated with siRNA targeting Wnt2 and b-catenin Similar to the results obtained from the in vitro study, the expression of Wnt2, Fz2, p-GSK3b, b-catenin, cyclin D1, PI3K and p-AKT in tumor specimens from Wnt2-or b-catenin siRNA-treated mice was prominently downregulated, whereas the c-Myc expression was not affected (Figures 4c and d) . There was no significant difference between tumors treated with Wnt2 or b-catenin siRNA either. However, the downregulation of PI3K signaling in Wnt2/b-catenin siRNA-treated tumors further demonstrated that cross-talk might exist between the Wnt and PI3K pathways.
Detection of cell apoptosis in tumor samples treated with Wnt2 and b-catenin siRNA Cell apoptosis in tumor samples derived from control and treated mice was examined by the TUNEL method, which showed that the number of apoptotic cells was dramatically increased in the tumors treated with Wnt2 or b-catenin siRNA as compared with those in tumor specimens from control or scr-siRNA-treated mice (Figures 5a and b) . There was no difference in cell apoptosis induced by either Wnt2 or b-catenin siRNA.
Discussion
Malignant glioma is a highly invasive and challenging tumor of the central nervous system. Currently available Wnt2/b-catenin in glioma P Pu et al The Wnt signaling pathway is essential for development and increasing evidence indicates that inappropriate activation of the Wnt pathway is broadly involved in oncogenesis. A number of Wnt genes, including Wnt1, Wnt2, Wnt3a, Wnt5a, Wnt7a, Wnt7b, Wnt10b and Wnt13, have been associated with cell transformation and some tumor development. 4, 5, 11, 14, 17, 18 However, the report on the activation of Wnts in human brain tumors is (35/45, 78%) were expressed in most brain tumors, but no differential expression was observed among three histopathological types of tumors, whereas Wnt1 was less expressed (6/45, 13%). However, no normal brain tissues were used as control in the study. In our present study, the expression of seven Wnts (Wnt1, Wnt2, Wnt3, Wnt4, Wnt5a, Wnt10b and Wnt13), two Fzs (Fz2 and Fz5) and bcatenin, was examined in 45 astrocytic gliomas and 4 normal brain tissues by RT-PCR analysis. It was observed that Wnt2, Wnt5a and Fz2 were not expressed in normal brain tissues, but overexpressed in gliomas, and their expression levels were correlated positively with the tumor grades. Similar observations were demonstrated by immunohistochemical staining. Wnt2 has been reported to be upregulated in gastric cancer, CRC, melanoma, nonsmall cell lung cancer and mesothelioma. [19] [20] [21] [22] However, the expression of Wnt2 in gliomas has not been reported earlier. On the basis of our results from the present study, it seems that Wnt2 is also overexpressed in gliomas.
It should be noted that b-catenin mRNA expression in glioma samples shows no significant difference with that of normal brain tissues as detected by RT-PCR. However, immunohistochemistry shows that b-catenin protein expression is lower in normal brain as compared with glioma samples. This finding suggests that b-catenin overexpression in gliomas may not result from increased transcription, but is likely due to the reduced degradation and accumulation. Accumulation of b-catenin protein has been identified as a key oncogenic process in the development of cancers. Utsuki et al. 23 examined the expression of b-catenin together with N-cadherin in 45 astrocytic gliomas of different grades by immunohistochemistry and found that their expression levels were elevated with the ascending order of the tumor grade. The activation or mutation of its upstream components, such as Wnt activation, APC and axin mutation and aberration of some other related molecules, may lead to the stabilization and accumulation of b-catenin. In addition, mutation of the b-catenin (CTNNB1) gene may also prevent its phosphorylation and degradation. CTNNB1 gene has been found to be mutated in a variety of tumors. 2, 8, [24] [25] [26] [27] [28] Most of the CTNNB1 gene mutations occur in or around exon 3 of the CTNNB1 gene, affecting the phosphorylation sites for GSK3b and rendering b-catenin refractory to degradation. There are a few reports on the mutation of b-catenin in brain tumors, including medulloblastomas, pituitary adenomas, craniopharyngiomas and astrocytic gliomas. However, the frequency of missense mutation in exon 3 of the CTNNB1 gene is significantly lower than the accumulation of b-catenin, [28] [29] [30] [31] which, taking into account these limited data, suggests that mutation of the CTNNB1 gene may be not a major molecular event that results in the accumulation of b-catenin in the aberration of the Wnt/b-catenin pathway in either astrocytic gliomas or other types of brain tumors.
As the Wnt2 activation and b-catenin accumulation are the hallmark of an active canonical Wnt pathway, which is strongly involved in tumorigenesis, the silencing effect of Wnt2 and b-catenin expression by RNA interference on the cell growth of malignant gliomas are studied both in vitro and in vivo.
The in vitro studies have shown that transfection with Wnt2 or b-catenin siRNA reduces the cell viability and invasive ability, whereas the apoptosis is induced. Transfection with Wnt2 or b-catenin siRNA downregulates the expression of not only Wnt2, b-catenin and its downstream effector, cyclin D1, but also PI3K and p-AKT. However, c-Myc overexpression is not affected by the siRNA transfection. There is no apparent difference between the effect of Wnt2 and b-catenin siRNA on the suppression of the malignant phenotype in U251 cells. As expected, the b-catenin expression decreased in U251 cells transfected with Wnt2 siRNA. However, when b-catenin siRNA was transfected to U251 cells, Wnt2 expression in the upstream of the signaling pathway was also downregulated, which seems unexpected. We believe that this is not due to the off-target effect as b-catenin-specific sequence has been searched through Blast to avoid the homology to other genes as described by Bouguignon et al. 32 The signaling cascades usually do not operate in isolation, but integrate stimuli in cross-talked pathways and may have reciprocal feedback regulation. Similarly, a signaling cascade not only transmits the effects to the downstream members, a possibility may also exist that a feedback mechanism transmits information upwards, as suggested by Ventura et al. 33 This observation and its underlying mechanism should be further investigated.
The results of the in vivo studies further confirm that Wnt2 or b-catenin siRNA inhibits the cell growth of xenograft subcutaneous gliomas. Meanwhile, decreased expression of Wnt2 and b-catenin is consistent with the downregulation of Fz2, p-GSK3b, cyclin D1, PI3K and p-AKT expression in tumors treated with target siRNAs, whereas c-Myc expression level remains unchanged. The c-Myc is known to be one of the downstream targets of the Wnt pathway and there is synergistic action between Wnt and c-Myc in promoting oncogenic transformation through the inhibition of apoptosis. 34 However, knockdown of Wnt/b-catenin signaling fails to inhibit c-Myc expression in U251 cells in the present study. Kolligs et al. 35 reported that mutated b-catenin transforms RK3E, an EIA-immortalized epithelial cell line derived from neonatal rat kidney, and is not consistently increased in c-Myc expression. The phenotypes of b-catenin transformed RK3E cell line lacking increased c-Myc expression reveals no differences with those cell lines with elevated c-Myc expression. Takayama et al. 36 also found that downregulation of b-catenin in U2OS/GR cells transfected with b-catenin siRNA suppresses cyclin D1 but not c-Myc expression. Thus, the result of our present study supports the view that c-Myc might not be a critical target of Wnt/b-catenin signaling-mediated oncogenic events.
Knockdown of Wnt/b-catenin simultaneously suppresses the activation of the PI3K/AKT pathway, which is one of the most important downstream effectors of EGFR, suggesting the cross-talk between Wnt/b-catenin and PI3K/AKT pathways. Tan et al. 37 found that the transgenic mice overexpressing b-catenin in liver showed increased EGFR expression. The direct interaction of Wnt/b-catenin signaling and EGFR/erbB2 heterodimers has also been identified in mammary tumors. 38 In addition, a cross-talk has been reported between the Wnt and the Hedgehog (Hh) as well as the Notch signaling pathways in the tumorigenesis. 39, 40 Using microarray analysis, Huang et al. 41 demonstrated that some important signaling pathways, such as PTEN-PI3K-AKT, NF-kB and p53, were involved in the apoptosis of HeLa cells induced by silencing of b-catenin expression. Taken together, these data indicate that direct and indirect links of Wnt/b-catenin with other signaling pathways are intertwining and complex. Further studies are needed to explore the precise mechanism underlying the Wnt/b-catenin pathway in oncogenesis.
In summary, results of the present study demonstrate that knockdown of the canonical Wnt signaling pathway using Wnt2 or b-catenin siRNA effectively suppresses the malignant glioma cell growth. RNA interference against Wnt2 and b-catenin has similar effects in the inhibition of cell proliferation of malignant pleural mesothelioma and pediatric hepatic tumors. 19, 42 Therefore, the canonical Wnt signaling pathway may be a potential new therapeutic target for various human cancers. 43 
